Who is sponsoring NCT06700421?

NCT06700421 is sponsored by Wei Zhou.

What drugs are being tested in NCT06700421?

Interventions in NCT06700421: Adebrelimab + Apatinib.

What condition does NCT06700421 study?

NCT06700421 studies Unresectable Locally Advanced Non-small Cell Lung Cancer.

Is NCT06700421 still recruiting?

NCT06700421 is currently active, enrolled. Last updated 22 November 2024.

Last reviewed 2024-11-22 · How we verify

NCT06700421

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis

Active, enrolled Phase 2 Last updated 22 November 2024

What this trial tests

Phase 2 trial testing Adebrelimab + Apatinib in Unresectable Locally Advanced Non-small Cell Lung Cancer in 32 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

13 August 2024

Primary endpoint
31 December 2024

31 December 2026

Quick facts

Lead sponsor	Wei Zhou
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	32
Start date	13 August 2024
Primary completion	31 December 2024
Estimated completion	31 December 2026
Sites	1 location across China

Drugs / interventions tested

Adebrelimab + Apatinib — full drug profile →

Conditions studied

Unresectable Locally Advanced Non-small Cell Lung Cancer — all drugs for Unresectable Locally Advanced Non-small Cell Lung Cancer →

Sponsor

Wei Zhou — full company profile →

Who can join

18 and older, any sex, with Unresectable Locally Advanced Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective, single-center, phase II clinical study of adebrelimab combined with apatinib in the treatment of unresectable stage III NSCLC patients with grade ≤2 radiation pneumonitis after definitive chemoradiotherapy

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Critical Review of Immunomodulation in the Management of Inoperable Stage III NSCLC.
Burcher K, Karukonda P, Kelsey C, Mullikin T, et al · · 2025 · cited 3× · PMID 40507315 · DOI 10.3390/cancers17111829

Verify or expand the search:

Other trials of Adebrelimab + Apatinib

Trials testing the same drug.

NCT06764368 — Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors · Phase 2 · not yet recruiting
NCT06773156 — Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer · Phase 2 · enrolling by invitation

Other Wei Zhou trials

Trials by the same sponsor.

NCT06587178 — Semi-elemental Versus Polymeric EEN in the Preoperative Optimization for Patients with CD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06700421 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wei Zhou
Last refreshed: 22 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06700421.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing